Background: There are diverse causes of cicatricial alopecia characterized by lack of follicular ostia and irreversible loss of hair. While clinical differentiation between the causes may be difficult, particularly with regard to lichen planus (LP), lupus erythematosus (LE) and pseudopelade of Brocq (PB), it has been suggested that both histopathologic examination and direct immunofluorescence studies (DIF) are necessary for an accurate diagnosis. Objective: The aim of this study was to evaluate the diagnostic value of DIF studies in addition to histopathology in patients with cicatricial alopecia as a clinical feature. Methods: 136 scalp biopsy specimens received for histopathology and DIF during a 5-year period were reviewed. Results: Definitive diagnosis was achieved by careful evaluation of scalp biopsies. The most prevalent diagnoses in order of frequency were LP (26%), LE (21%) and folliculitis decalvans (20%). PB was diagnosed in 10%. In most cases, the diagnosis could be made on the basis of histopathology and independently of DIF. Characteristic DIF patterns showed high specificity, but low sensitivity for LP, and high specificity and sensitivity for LE. The DIF pattern in PB showed no difference to LP. Conclusions: Histopathology permits diagnosis in the majority of cicatricial alopecias. DIF is of value in histopathologically inconclusive cases, particularly when LE is in question.

Keywords:
Scarring alopecia, Histopathology, Direct immunofluorescence, Lupus erythematosus, Lichen planopilaris, Pseudopelade of Brocq
1.
Mehregan DA, Van Hale HM, Muller SA: Lichen planopilaris: Clinical and pathologic study of forty-five patients. J Am Acad Dermatol 1992;27:935–942.
2.
Amato L, Mei S, Massi D, et al: Cicatricial alopecia: A dermatopathologic and immunopathologic study of 33 patients (pseudopelade of Brocq is not a specific clinicopathologic entity). Int J Dermatol 2002;41:8–15.
3.
Amato L, Massi D, Berti S, et al: A multiparametric approach is essential to define different clinicopathological entities within pseudopelade of Brocq. Br J Dermatol 2002;146:532–533.
4.
Silver H, Chargin L, Sachs P: Follicular lichen planus (lichen planopilaris). Arch Dermatol 1953;67:346–354.
5.
Smith WB, Grabski WJ, McCollough ML, Davis TL: Immunofluorescence findings in lichen planopilaris: A contrasting experience. Arch Dermatol 1992;128:1405–1406.
6.
Sperling LC: Scarring alopecia and the dermatopathologist. J Cutan Pathol 2001;28:333–342.
7.
Anderton RL, Cullen SI: Pseudopelade of Brocq secondary to lichen planus. Cutis 1976;17:916–918.
8.
Braun-Falco O, Imai S, Schmoeckel C, et al: Pseudopelade of Brocq. Dermatologica 1986;172:18–23.
9.
Silvers DN, Katz BE, Young AW: Pseudopelade of Brocq is lichen planopilaris: Report of four cases that support this nosology. Cutis 1993;51:99–105.
10.
Piérard-Franchimont C, Piérard GE: Massive lymphocyte-mediated apoptosis during the early stage of pseudopelade. Dermatologica 1986;172:254–257.
11.
Jordon RE: Subtle clues to diagnosis by immunopathology: Scarring alopecia. Am J Dermatopathol 1980;2:157–159.
12.
Abell E: Immunofluorescent staining technics in the diagnosis of alopecia. South Med J 1977;70:1407–1410.
13.
Whiting DA: Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol 2001;19:211–225.
14.
Ueki H: Hyaline bodies in subepidermal papillae: Immunohistochemical studies in several dermatoses. Arch Dermatol 1969;100:610–617.
15.
Baart de la Faille-Kuyper EH, Baart de la Faille H: An immunofluorescence study of lichen planus. Br J Dermatol 1974;90:365–371.
16.
Abell E, Presbury DGC, Marks R, Ramnarain D: The diagnostic significance of immunoglobulin and fibrin deposition in lichen planus. Br J Dermatol 1975;93:17–24.
17.
Gogate P, Valenzuela R, Deodhar S, et al: Globular deposits of immunoglobulins and complement in the papillary dermis: Clinical significance. Am J Clin Pathol 1980;73:512–517.
18.
Anonymous: Uses for immunofluorescence tests of skin and sera: Utilization of immunofluorescence in the diagnosis of bullous diseases, lupus erythematosus, and certain other dermatoses. Arch Dermatol 1975;111:371–381.
19.
Monroe EW: Lupus band test. Arch Dermatol 1977;113:830–834.
20.
Harrist TJ, Mihm MC: Cutaneous immunopathology. The diagnostic use of direct and indirect immunofluorescence techniques in dermatologic disease. Hum Pathol 1979;10:625–653.
21.
Tuffanelli DL, Kay D, Fukuyama K: Dermal-epidermal junction in lupus erythematosus. Arch Dermatol 1969;99:652–662.
22.
Chorzelski T, Jablonska S, Blaszczyk M: Immunopathologic investigations in lupus erythematosus. J Invest Dermatol 1969;52:333–338.
23.
Burnham TK, Fine G: The immunofluorescent ‘band’ test for lupus erythematosus. I. Morphologic variations of the band of localized immunoglobulins at the dermal-epidermal junction in lupus erythematosus. Arch Dermatol 1969;99:413–420.
24.
Burnham TK, Fine G, Neblett TR: Immunofluorescent ‘band’ test for lupus erythematosus. II. Employing skin lesions. Arch Dermatol 1970;102:42–50.
25.
Annessi G, Lombardo G, Gobello T, Puddu P: A clinicopathologic study of scarring alopecia due to lichen planus: Comparison with scarring alopecia in discoid lupus erythematosus and pseudopelade. Am J Dermatopathol 1999;21:324–331.
26.
Coons AH, Kaplan MH: Location of antigen in tissue cells. II. Improvements in a method for the detection of antigen by means of fluorescent antibody. J Exp Med 1950;91:1–13.
27.
O’Loughlin S, Schroeter AL, Jordon RE: A study of lupus erythematosus with particular reference to generalized discoid lupus. Br J Dermatol 1978;99:1–11.
28.
Salo OP, Tallberg T, Mustakallio KK: Demonstration of fibrin in skin diseases. I. Lichen ruber planus and lupus erythematosus. Acta Derm Venereol 1972;52:291–294.
29.
Elston DM, McCollough ML, Angeloni VL: Vertical and transverse sections of alopecia biopsy specimens: Combining the two to maximize diagnostic yield. J Am Acad Dermatol 1995;32:454–457.
30.
Kossard S: Postmenopausal frontal fibrosing alopecia: Scarring alopecia in a pattern distribution. Arch Dermatol 1994;130:770–774.
31.
Sperling LC, Sau P: The follicular degeneration syndrome in black patients: ‘Hot comb alopecia’ revisited and revised. Arch Dermatol 1992;128:68–74.
32.
Kossard S: Diffuse alopecia with stem cell folliculitis: Chronic diffuse alopecia areata or a distinct entity? Am J Dermatopathol 1999;21:46–50.
33.
Tan E, Martinka M, Ball N, Shapiro J: Primary cicatricial alopecias: Clinicopathology of 112 cases. J Am Acad Dermatol 2004;50:25–32.
34.
Degos P, Rabut R, Duperrat B, Leclercq R: Pseudopeladic state: Comments on one hundred cases of circumscribed cicatricial alopecia, apparently primary, of pseudopelade type. Ann Dermatol Syphiligr (Paris) 1954;81:5–26.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.